Esperion Therapeutics (NASDAQ:ESPR) Raised to Buy at Wall Street Zen

Key Points

• Esperion Therapeutics has been upgraded from a "hold" rating to a "buy" rating by Wall Street Zen, indicating a more optimistic outlook for the company.
• HC Wainwright has also restated a "buy" rating for Esperion with a price target of $16.00, while the consensus target price currently stands at $7.00.
• The company reported a revenue of $82.39 million for the recent quarter, surpassing analysts' expectations by a significant margin.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Friday.

Separately, HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Price Performance

ESPR traded up $0.09 during trading on Friday, hitting $2.65. 5,392,303 shares of the stock traded hands, compared to its average volume of 6,876,379. The firm has a market capitalization of $534.29 million, a P/E ratio of -5.41, a price-to-earnings-growth ratio of 57.50 and a beta of 0.89. The firm has a 50-day moving average of $2.11 and a 200 day moving average of $1.46. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.15. The business had revenue of $82.39 million during the quarter, compared to analysts' expectations of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. As a group, equities analysts predict that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ESPR. Nuveen LLC bought a new position in shares of Esperion Therapeutics in the 1st quarter worth about $4,446,000. Two Seas Capital LP increased its stake in Esperion Therapeutics by 43.6% during the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company's stock valued at $9,800,000 after purchasing an additional 3,024,104 shares in the last quarter. Marshall Wace LLP increased its stake in Esperion Therapeutics by 46.2% during the 2nd quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company's stock valued at $5,206,000 after purchasing an additional 1,679,294 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Esperion Therapeutics by 48.6% during the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Esperion Therapeutics by 45.1% during the 4th quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock valued at $3,586,000 after purchasing an additional 506,428 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.